Pathophysiology Department, "Iuliu Hațieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Department of Food Science and Technology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Curr Pharm Des. 2019;25(18):2038-2050. doi: 10.2174/1381612825666190708190437.
There is an urgent need for a better understanding and management of obesity and obesity- associated diseases. It is known that obesity is associated with structural and functional changes in the microbiome.
The purpose of this review is to present current evidence from animal and human studies, demonstrating the effects and the potential efficacy of microbiota modulation in improving obesity and associated metabolic dysfunctions.
This review discusses possible mechanisms linking gut microbiota dysbiosis and obesity, since there is a dual interaction between the two of them. Furthermore, comments on bariatric surgery, as a favourable model to understand the underlying metabolic and inflammatory effects, as well as its association with changes in the composition of the gut microbiota, are included. Also, a possible impact of anti-obesity drugs and the novel antidiabetic drugs on the gut microbiota has been briefly discussed.
More research is needed to better understand here discussed the association between microbiota modulation and obesity. It is expected that research in this field, in the following years, will lead to a personalized therapeutic approach considering the patient's microbiome, and also give rise to the discovery of new drugs and/or the combination therapies for the management of obesity and obesity-related co-morbidities.
人们急需更好地了解和治疗肥胖症及其相关疾病。目前已知肥胖与微生物组的结构和功能变化有关。
本综述旨在介绍动物和人体研究的现有证据，证明微生物组调节在改善肥胖症和相关代谢功能障碍方面的效果和潜在疗效。
本综述讨论了肠道微生物组失调与肥胖之间可能存在的联系，因为它们之间存在双向相互作用。此外，还对减肥手术进行了评论，减肥手术是了解潜在代谢和炎症影响的有利模型，以及它与肠道微生物组组成变化的关联。还简要讨论了抗肥胖药物和新型抗糖尿病药物对肠道微生物组的可能影响。
需要进一步研究以更好地了解微生物组调节与肥胖之间的关联。预计未来几年，该领域的研究将导致考虑患者微生物组的个性化治疗方法，并为肥胖症和肥胖相关合并症的管理发现新的药物和/或联合疗法。
